Compass Pathways Drops Nearly 10% After Psilocybin Trial Data Disappoint Investors
2026-07-07 15:14:41
Compass Pathways Plc shares fell almost 10% Tuesday after a pivotal study of its experimental psilocybin-based therapy reinforced the drug’s durability for treatment-resistant depression but left investors underwhelmed by efficacy details, according to Bloomberg.
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
Previous article：
先锋集团招聘数字资产主管，仍无意推比特币ETF
